⌘K
Loading ticker…
Kairos Pharma, Ltd. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Kairos Pharma, Ltd. (KAPA) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 32. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.1%, relative volume 4.09×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
7 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
KAPA is in a stage 4 downtrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -31.5% / -54.3%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
KAPA appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $38K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $38K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KAPA Jan avg: -6.17% median: -6.17% win: 0% σ: 0.36% n: 2 2024-09-17 → 2026-05-29 | KAPA Feb avg: -12.82% median: -12.82% win: 0% σ: 5.60% n: 2 2024-09-17 → 2026-05-29 | KAPA Mar avg: -14.50% median: -14.50% win: 0% σ: 9.65% n: 2 2024-09-17 → 2026-05-29 | KAPA Apr avg: -6.15% median: -6.15% win: 50% σ: 10.21% n: 2 2024-09-17 → 2026-05-29 | KAPA May avg: -17.31% median: -17.31% win: 0% σ: 10.57% n: 2 2024-09-17 → 2026-05-29 | KAPA Jun avg: 16.23% median: 16.23% win: 100% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 (current) | KAPA Jul avg: 26.95% median: 26.95% win: 100% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 | KAPA Aug avg: 49.98% median: 49.98% win: 100% σ: 0.00% n: 1 2024-09-17 → 2026-05-29 | KAPA Sep avg: -26.47% median: -26.47% win: 0% σ: 18.58% n: 2 2024-09-17 → 2026-05-29 | KAPA Oct avg: -9.99% median: -9.99% win: 0% σ: 9.29% n: 2 2024-09-17 → 2026-05-29 | KAPA Nov avg: -4.33% median: -4.33% win: 50% σ: 30.96% n: 2 2024-09-17 → 2026-05-29 | KAPA Dec avg: -8.07% median: -8.07% win: 0% σ: 9.57% n: 2 2024-09-17 → 2026-05-29 |